POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study

01/23/26

POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study

Digna T. de Bruin, Manon A. A. Jansen, Diana R. Pereira, Lisa van Schijndel, Erica S. Klaassen, Marije E. Otto, Jeremy Skillington, Paula Maguire, Liam Tremble, Alan Bell, Laura Maher, Katsuhiro Mihara, Mark Sumeray,...

POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study

Poolbeg Pharma
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.